(0.81%) 5 059.01 points
(0.76%) 38 192 points
(1.35%) 15 817 points
(-0.01%) $78.99
(5.02%) $2.03
(0.29%) $2 317.70
(0.58%) $26.90
(1.09%) $965.35
(-0.05%) $0.933
(-0.35%) $10.99
(-0.04%) $0.798
(-1.36%) $91.99
4 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 12.28%
@ $5.48
Išleistas: 14 vas. 2024 @ 22:23
Grąža: -17.08%
Ankstesnis signalas: vas. 14 - 19:19
Ankstesnis signalas:
Grąža: 1.96 %
Live Chart Being Loaded With Signals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema...
Stats | |
---|---|
Šios dienos apimtis | 624 129 |
Vidutinė apimtis | 3.27M |
Rinkos kapitalizacija | 936.74M |
EPS | $0 ( 2024-05-01 ) |
Kita pelno data | ( $-0.230 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.85 |
ATR14 | $0.00800 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
75.16 |
Last 100 transactions |
Buy: 4 343 991 | Sell: 822 588 |
Tūris Koreliacija
BioCryst Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
NAKD | 0.945 |
SNGX | 0.941 |
GSMG | 0.94 |
MICS | 0.938 |
CSSEP | 0.932 |
TENX | 0.931 |
GRNA | 0.931 |
IRBT | 0.93 |
BCYC | 0.93 |
BHTG | 0.928 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GXII | -0.959 |
MLTX | -0.944 |
NCAC | -0.944 |
LMNR | -0.944 |
VPCB | -0.943 |
TETC | -0.941 |
LMRKO | -0.939 |
PPYAU | -0.938 |
FTPA | -0.937 |
CRZN | -0.936 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
BioCryst Pharmaceuticals Koreliacija - Valiuta/Žaliavos
BioCryst Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $331.41M |
Bruto pelnas: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2023 |
Pajamos: | $331.41M |
Bruto pelnas: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2022 |
Pajamos: | $270.83M |
Bruto pelnas: | $264.23M (97.57 %) |
EPS: | $-1.330 |
FY | 2021 |
Pajamos: | $157.17M |
Bruto pelnas: | $149.91M (95.38 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.